VERA vs. ASND, CERE, ITCI, JAZZ, BPMC, VKTX, IONS, CYTK, SMMT, and OGN
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Summit Therapeutics (SMMT), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical preparations" industry.
Ascendis Pharma A/S (NASDAQ:ASND) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends.
Vera Therapeutics has a net margin of 0.00% compared to Vera Therapeutics' net margin of -152.68%. Ascendis Pharma A/S's return on equity of -52.43% beat Vera Therapeutics' return on equity.
In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 6 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.11 beat Ascendis Pharma A/S's score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.
Ascendis Pharma A/S received 386 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 65.45% of users gave Ascendis Pharma A/S an outperform vote while only 55.56% of users gave Vera Therapeutics an outperform vote.
Vera Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Vera Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Ascendis Pharma A/S currently has a consensus target price of $179.44, indicating a potential upside of 30.82%. Vera Therapeutics has a consensus target price of $42.86, indicating a potential upside of 11.32%. Given Vera Therapeutics' higher possible upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Vera Therapeutics.
Ascendis Pharma A/S has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
99.2% of Vera Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 21.7% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Ascendis Pharma A/S and Vera Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vera Therapeutics Competitors List
Related Companies and Tools
